Evaluating Disitamab vedotin for breast cancer treatment
Disitamab Vedotin (RC48-ADC) in Patients With Breast Cancer: a Real-world Study
This study is testing how well Disitamab vedotin works and how safe it is for people with breast cancer who have used or are using this treatment.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 45 (estimated) |
| Sex | All |
| Sponsor | RenJi Hospital Academic / other |
| Drugs / interventions | Disitamab |
| Locations | 1 site (Shanghai) |
| Trial ID | NCT05851677 on ClinicalTrials.gov |
What this trial studies
This observational study aims to assess the efficacy and safety of Disitamab vedotin (RC48-ADC) in patients diagnosed with breast cancer. Participants will include individuals who have either previously used or are currently using this treatment. The study will gather data on patient outcomes and side effects to better understand the drug's impact on breast cancer management.
Who should consider this trial
Good fit: Ideal candidates are patients with histologically confirmed breast cancer who have prior or current experience with Disitamab vedotin.
Not a fit: Patients currently participating in other clinical trials involving Disitamab vedotin may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide valuable insights into the effectiveness of Disitamab vedotin for breast cancer patients.
How similar studies have performed: While this study focuses on a specific treatment, similar approaches have shown promise in other cancer therapies, indicating potential for success.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Histologically confirmed breast cancer; * Prior or current use of Disitamab vedotin (RC48-ADC); Exclusion Criteria: * Participating in clinical trials involving Disitamab vedotin (RC48-ADC) or not.
Where this trial is running
Shanghai
- Renji Hospital, School of Medicine, Shanghai Jiaotong University — Shanghai, China (Recruiting)
Study contacts
- Principal investigator: Wenjin Yin, M.D. — Renji Hospital,School of Medicine, Shanghai Jiaotong University
- Study coordinator: Wenjin Yin, M.D.
- Email: yinwenjin@renji.com
- Phone: 86(21)68385569
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.